🏛️ Verified NIH Record • Updated 2026-08-07

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer (NCT07647328)

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.

Who can join: Review the eligibility criteria below.

Location: Research Site — Duarte, California

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (89 Sites)

Showing the first 25 of 89 sites.

  • Research Site — Duarte, California
  • Research Site — Palo Alto, California
  • Research Site — Marietta, Georgia
  • Research Site — Evanston, Illinois
  • Research Site — Edgewood, Kentucky
  • Research Site — Louisville, Kentucky
  • Research Site — Reno, Nevada
  • Research Site — Sioux Falls, South Dakota
  • Research Site — Nashville, Tennessee
  • Research Site — Fort Worth, Texas
  • Research Site — Kingwood, Texas
  • Research Site — Midlothian, Virginia
  • Research Site — Angers,
  • Research Site — Bayonne,
  • Research Site — Bobigny,
  • Research Site — Caen,
  • Research Site — Chambray-lès-Tours,
  • Research Site — Grenoble,
  • Research Site — Montpellier,
  • Research Site — Nancy,
  • Research Site — Nîmes,
  • Research Site — Paris,
  • Research Site — Pierre-Bénite,
  • Research Site — Valenciennes,
  • Research Site — Vandœuvre-lès-Nancy,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in ER-Positive HER2-Negative Breast Cancer

Explore by condition: All ER-Positive HER2-Negative Breast Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗